Subscribe to RSS
DOI: 10.1055/a-2679-6152
Risk of Cancer in the Short and Long Term after Incident Venous Thromboembolism: The HUNT and Tromsø Studies

Abstract
Background
Venous thromboembolism (VTE) has long been recognized as a harbinger of cancer. The epidemiology of VTE and cancer has evolved over the past decades, and contemporary data addressing the association between VTE and subsequent risk of cancer are needed.
Objectives
We aimed to investigate the short- (≤1 year) and long-term (>1 year) risk of cancer after incident VTE in a population-based cohort study.
Methods
A total of 111,119 participants from Tromsø4–7 (1994–2016) and HUNT2–3 (1995–2008) surveys were followed through 2020, and all first-lifetime cancer and VTE events were recorded. Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for cancer diagnosis in participants with VTE compared with those without VTE, with VTE being modeled as a time-varying exposure.
Results
Among the 2,506 individuals with incident VTE, 417 had a subsequent diagnosis of incident cancer during a median follow-up after VTE of 5.2 years. In models adjusted for age (as a time-scale), sex, body mass index, smoking, and comorbidities, the HRs for cancer were 4.57 (95% CI 3.89–5.37) at 0 to 1 year, 1.19 (95% CI 0.93–1.52) at 1 to 3 years, and 1.14 (95% CI 0.99–1.31) at >3 years after overall VTE when compared with individuals without VTE, and the risk estimates were particularly pronounced at 0 to 1 year after unprovoked VTE (HR 5.63, 95% CI 4.67–6.77).
Conclusion
Our results indicate a transient and substantially increased risk of cancer diagnosis within 1 year after an incident VTE, and especially after unprovoked VTE.
Authors' Contribution
J.B.H. contributed to conception and design; K.H., S.K.B., and J.B.H. contributed to data collection; C.L. and S.K.B. contributed to statistical analysis; C.L., N.H.E., K.H., N.v.E., S.K.B., V.M.M., and J.B.H. contributed to interpretation of data; C.L., V.M.M., and J.B.H. contributed to draft of manuscript; C.L., N.H.E., K.H., N.v.E., S.K.B., V.M.M., and J.B.H. contributed to critical revision of manuscript. All co-authors reviewed and approved the final version.
Publication History
Received: 22 March 2025
Accepted: 07 August 2025
Accepted Manuscript online:
11 August 2025
Article published online:
25 August 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet 2021; 398 (10294): 64-77
- 2 Brækkan SK, Hansen J-B. VTE epidemiology and challenges for VTE prevention at the population level. Thromb Update 2023; 10: 100132
- 3 Arshad N, Isaksen T, Hansen JB, Brækkan SK. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur J Epidemiol 2017; 32 (04) 299-305
- 4 Münster AM, Rasmussen TB, Falstie-Jensen AM. et al. A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006–2015. Thromb Res 2019; 176: 46-53
- 5 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102 (Suppl. 01) S2-S9
- 6 Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338 (17) 1169-1173
- 7 Iodice S, Gandini S, Löhr M, Lowenfels AB, Maisonneuve P. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 2008; 6 (05) 781-788
- 8 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000; 342 (26) 1953-1958
- 9 Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004; 91 (01) 92-95
- 10 Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351 (9109) 1077-1080
- 11 Douketis JD, Gu C, Piccioli A, Ghirarduzzi A, Pengo V, Prandoni P. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009; 7 (04) 546-551
- 12 Sørensen HT, Sværke C, Farkas DK. et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer 2012; 48 (04) 586-593
- 13 Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Intern Med 2008; 149 (05) 323-333
- 14 van Es N, Le Gal G, Otten HM. et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med 2017; 167 (06) 410-417
- 15 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
- 16 Frischmuth T, Tøndel BG, Brækkan SK, Hansen JB, Morelli VM. The risk of incident venous thromboembolism attributed to overweight and obesity: the Tromsø study. Thromb Haemost 2024; 124 (03) 239-249
- 17 Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612) 569-578
- 18 Jørgensen H, Horváth-Puhó E, Laugesen K, Braekkan S, Hansen JB, Sørensen HT. Socioeconomic status and risk of incident venous thromboembolism. J Thromb Haemost 2021; 19 (12) 3051-3061
- 19 Uthman OA, Jadidi E, Moradi T. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. J Epidemiol Community Health 2013; 67 (10) 854-860
- 20 Evensen LH, Isaksen T, Hindberg K, Braekkan SK, Hansen JB. Repeated assessments of physical activity and risk of incident venous thromboembolism. J Thromb Haemost 2018; 16 (11) 2208-2217
- 21 McTiernan A, Friedenreich CM, Katzmarzyk PT. et al; 2018 Physical Activity Guidelines Advisory Committee*. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc 2019; 51 (06) 1252-1261
- 22 Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost 2008; 6 (11) 1851-1857
- 23 Rinde LB, Småbrekke B, Hald EM. et al. Myocardial infarction and future risk of cancer in the general population-the Tromsø study. Eur J Epidemiol 2017; 32 (03) 193-201
- 24 Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence?. Int Immunopharmacol 2015; 28 (01) 655-665
- 25 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420 (6917) 860-867
- 26 De Angelis R, Demuru E, Baili P. et al; EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol 2024; 25 (03) 293-307
- 27 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 28 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso study. Int J Epidemiol 2012; 41 (04) 961-967
- 29 Krokstad S, Langhammer A, Hveem K. et al. Cohort profile: the HUNT study, Norway. Int J Epidemiol 2013; 42 (04) 968-977
- 30 Åsvold BO, Langhammer A, Rehn TA. et al. Cohort profile update: the HUNT study, Norway. Int J Epidemiol 2023; 52 (01) e80-e91
- 31 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
- 32 Larsen IK, Småstuen M, Johannesen TB. et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45 (07) 1218-1231
- 33 Eischer L, Kammer M, Traby L, Kyrle PA, Eichinger S. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost 2017; 15 (07) 1368-1374
- 34 Hägg L, Ehrs F, Lind M, Johansson M. Cancer incidence and mortality after a first-ever venous thrombosis: a cohort study in northern Sweden. Thromb J 2024; 22 (01) 77
- 35 Wacholder S, Hartge P, Lubin JH, Dosemeci M. Non-differential misclassification and bias towards the null: a clarification. Occup Environ Med 1995; 52 (08) 557-558
- 36 Hu JX, Zhao CF, Chen WB. et al. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27 (27) 4298-4321
- 37 van Es N, Hisada Y, Di Nisio M. et al. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018; 166: 54-59
- 38 Frere C, Font C, Esposito F, Crichi B, Girard P, Janus N. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Support Care Cancer 2022; 30 (04) 2919-2931
- 39 Yachida S, Jones S, Bozic I. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467 (7319) 1114-1117
- 40 Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371 (11) 1039-1049
- 41 Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130 (13) 1499-1506
- 42 Lv X, Gao X, Liu J. et al. Immune-mediated inflammatory diseases and risk of venous thromboembolism: a Mendelian randomization study. Front Immunol 2022; 13: 1042751
- 43 Robin P, Otten HM, Delluc A. et al. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thromb Res 2018; 171: 92-96
- 44 Jara-Palomares L, Otero R, Jimenez D. et al; RIETE Investigators. Development of a risk prediction score for occult cancer in patients with VTE. Chest 2017; 151 (03) 564-571
- 45 Ihaddadene R, Corsi DJ, Lazo-Langner A. et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood 2016; 127 (16) 2035-2037
- 46 Mulder FI, Carrier M, van Doormaal F. et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: results from an individual patient data meta-analysis. J Thromb Haemost 2020; 18 (10) 2622-2628
- 47 Rubin R. Questions swirl around screening for multiple cancers with a single blood test. JAMA 2024; 331 (13) 1077-1080
- 48 Clarke R, Shipley M, Lewington S. et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150 (04) 341-353
- 49 Småbrekke B, Rinde LB, Hindberg K. et al. Atherosclerotic risk factors and risk of myocardial infarction and venous thromboembolism; time-fixed versus time-varying analyses. The Tromsø study. PLoS One 2016; 11 (09) e0163242
- 50 Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007; 17 (09) 643-653